|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,360.00 KRW | +11.79% |
|
-9.45% | -36.81% |
| 01-25 | Sands Lab Inc to pay dividend of 150 won per common share | RE |
| 01-25 | SANDS LAB Inc. announces Annual dividend, payable on April 22, 2026 | CI |
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
Revenues | 8.3B | 11.61B |
Total Revenues | 8.3B | 11.61B |
Gross Profit | 8.3B | 11.61B |
Selling General & Admin Expenses, Total | 9.74B | 10.22B |
Provision for Bad Debts | -50.47M | -368K |
R&D Expenses | 1.52B | 2.02B |
Depreciation & Amortization - (IS) | 708M | 1B |
Amortization of Goodwill and Intangible Assets - (IS) | 83.18M | 134M |
Other Operating Expenses, Total | 12.01B | 13.38B |
Operating Income | -3.71B | -1.77B |
Interest Expense, Total | -9.34M | -354K |
Interest And Investment Income | 1.37B | 1.01B |
Net Interest Expenses | 1.36B | 1.01B |
Other Non Operating Income (Expenses) | -52.32M | -64.48M |
EBT, Excl. Unusual Items | -2.4B | -823M |
Gain (Loss) On Sale Of Investments | -391M | 783M |
Gain (Loss) On Sale Of Assets | 2.56M | 2.89M |
EBT, Incl. Unusual Items | -2.79B | -37.02M |
Income Tax Expense | -487M | 428M |
Earnings From Continuing Operations | -2.3B | -465M |
Net Income to Company | -2.3B | -465M |
Minority Interest | - | -84.18M |
Net Income - (IS) | -2.3B | -550M |
Net Income to Common Incl Extra Items | -2.3B | -550M |
Net Income to Common Excl. Extra Items | -2.3B | -550M |
Per Share Items | ||
Net EPS - Basic | -162 | -36.23 |
Basic EPS - Continuing Operations | -162 | -36.23 |
Basic Weighted Average Shares Outstanding | 14.2M | 15.17M |
Net EPS - Diluted | -162 | -36.23 |
Diluted EPS - Continuing Operations | -162 | -36.23 |
Diluted Weighted Average Shares Outstanding | 14.2M | 15.17M |
Normalized Basic EPS | -105.6 | -39.45 |
Normalized Diluted EPS | -105.6 | -39.45 |
Supplemental Items | ||
EBITDA | -2.92B | -633M |
EBITA | -3.63B | -1.64B |
EBIT | -3.71B | -1.77B |
Effective Tax Rate - (Ratio) | 17.47 | -1.16K |
Normalized Net Income | -1.5B | -599M |
Supplemental Operating Expense Items | ||
Selling and Marketing Expenses | 5.69B | 5.84B |
Research And Development Expense From Footnotes | 1.52B | 2.02B |
Stock-Based Comp., SG&A Exp. (Total) | 35.02M | - |
Total Stock-Based Compensation | 35.02M | - |
- Stock Market
- Stocks
- A411080 Stock
- Financials SANDS LAB Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















